FR 122047 hydrochloride
Selective cyclooxygenase-1 (COX-1) inhibitor (IC50 values are 0.028 and 65 μM for COX-1 and COX-2 respectively). Antiplatelet, analgesic and anti-inflammatory following oral administration in vivo.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 459.99. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.17 mL||10.87 mL||21.74 mL|
|5 mM||0.43 mL||2.17 mL||4.35 mL|
|10 mM||0.22 mL||1.09 mL||2.17 mL|
|50 mM||0.04 mL||0.22 mL||0.43 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Dohi et al (1993) The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor. Eur.J.Pharmacol. 243 179 PMID: 8276067
Ochi et al (2000) The analgesic effect profile of FR122047, a selective cyclo-oxygenase-1 inhibitor, in chemical nociceptive models. Eur.J.Pharmacol. 391 49 PMID: 10720634
Ochi and Goto (2002) Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritis. Br.J.Pharmacol. 135 782 PMID: 11834626
Tanaka et al (1994) Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles. J.Med.Chem. 37 1189 PMID: 8164261
If you know of a relevant reference for FR 122047 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: FR 122047 hydrochloride, supplier, Cyclooxygenase, COX-1, inhibitors, inhibits, Oxygenases, Oxidases, FR122047, hydrochloride, Cyclooxygenase, Cyclooxygenase, Tocris Bioscience
6 Citations for FR 122047 hydrochloride
Citations are publications that use Tocris products. Selected citations for FR 122047 hydrochloride include:
Tunaru et al (2012) Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors. PLoS One 109 9179 PMID: 22615395
Chia et al (2011) Protection of protease-activated receptor 2 mediated vasodilatation against angiotensin II-induced vascular dysfunction in mice. BMC Pharmacol 11 10 PMID: 21955547
Passafaro et al (2011) Cholinergic Autoantibodies from Primary Sjögren's Syndrome Inhibit Mucin Production via Phospholipase C and Cyclooxygenase-2 In the Rat Submandibular Gland. J Virol 8 138 PMID: 22013477
Ray et al (2004) Cyclooxygenase-1 and -2 are required for production of infectious pseudorabies virus. Proc Natl Acad Sci U S A 78 12964 PMID: 15542648
Tunaru et al (2016) Arachidonic acid metabolite 19(S)-HETE induces vasorelaxation and platelet inhibition by activating prostacyclin (IP) receptor. PLoS One 11 e0163633 PMID: 27662627
Lu et al (2013) Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. J Biol Chem 8 e65023 PMID: 23741443
Do you know of a great paper that uses FR 122047 hydrochloride from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.